Notable points conveyed by Merck (NYSE:MRK) CEO Ken Frazier in his investor presentation: Consumer business sales to Bayer (OTCPK:BAYRY) was 7x sales, expected to close in 2H; CV collaboration: Adempas (riociguat) launched in U.S., E.U. and Japan, Variciguat (BAY 102) in Phase 2 trial, $1B upfront payment to Bayer.
Cancer immunotherapy candidate MK-3475 BLA filed, granted priority review.
Nine Phase 3 trials underway; ten near-term new product launches possible; ten markets deliver 70% of MRK revenue; top 50 customers expected to deliver 50% of revenue by 2016.
Grow EPS off the 2014 base; deliver industry-leading ROC to shareholders.